Form 4: Lemaitre Vascular Inc. Executive Acquires Dividend Equivalent Rights
SEC Form 4 Filing
David B. Roberts, President and Director of Lemaitre Vascular Inc., reports the acquisition of dividend equivalent rights related to restricted stock unit awards.
Summary
- On March 28, 2024, David B. Roberts, President and Director of Lemaitre Vascular Inc., acquired dividend equivalent rights.
- These rights are associated with restricted stock unit (RSU) and Performance Share Unit (PSU) awards granted between December 2019 and December 2023.
- The acquired dividend equivalent rights are the economic equivalent of shares of Lemaitre Vascular's common stock and vest proportionately with the associated awards.
- The total dividend equivalent rights acquired are 0.8836, 1.6648, 3.1666, 4.8393, 4.8393, and 5.514 related to the awards granted on 12/20/2019, 12/2/2020, 12/11/2021, 12/12/2022, 12/12/2022, and 12/8/2023 respectively.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding executive compensation, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It reflects the ongoing vesting of previously granted equity awards.
Stakeholder Impact
- The acquisition of dividend equivalent rights has a minor impact on shareholders as it relates to the ongoing vesting of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 12/20/2019 | Date of restricted stock unit award grant related to dividend equivalent rights. |
| 12/02/2020 | Date of restricted stock unit award grant related to dividend equivalent rights. |
| 12/11/2021 | Date of restricted stock unit award grant related to dividend equivalent rights. |
| 12/12/2022 | Date of restricted stock unit and performance share unit award grant related to dividend equivalent rights. |
| 12/08/2023 | Date of restricted stock unit award grant related to dividend equivalent rights. |
| 03/28/2024 | Date of transaction: Acquisition of dividend equivalent rights. |
| 04/01/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.